Evidence for a functional Epo-EpoR system has been reported by several groups: intratumoural and intraperitoneal injections of solube EpoR or neutralizing monoclonal antibody to EpoR resulted in tumour growth delay and inhibition of angiogenesis (Yasuda et al, 2001, 2003; Arcasoy et al, 2002). The gene discussed is EPO; the disease is neoplasm.